Senescing oral dysplasias are not immortalized by ectopic expression of hTERT alone without other molecular changes, such as loss of INK4A and/or retinoic acid receptor-beta: but p53 mutations are not necessarily required

Oncogene. 2003 Oct 30;22(49):7804-8. doi: 10.1038/sj.onc.1207085.

Abstract

Our previous work showed that acquisition of immortality at the dysplasia stage of oral cancer progression was consistently associated with four changes: loss of retinoic acid receptor (RAR)-beta and p16INK4A expression, p53 mutations and activation of telomerase. One atypical dysplasia (D17) that underwent delayed senescence after an extended lifespan showed loss of RAR-beta and p16INK4A/p14ARF expression, but retained functional wild-type p53 and telomerase was not activated. We now demonstrate that retroviral delivery of hTERT results in telomere lengthening and immortalization of D17 without loss of functional wild-type p53 activity. In contrast, the expression of hTERT in two other typical mortal dyplasia cultures (that retain RAR-beta and p16INK4A expression) does not extend their lifespan, even though telomeres are lengthened.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cellular Senescence
  • Cyclin-Dependent Kinase Inhibitor p16 / physiology*
  • DNA-Binding Proteins
  • Genes, p53 / genetics*
  • Humans
  • Mouth Mucosa / pathology*
  • Mouth Neoplasms / pathology*
  • Mutation
  • Phosphorylation
  • Precancerous Conditions / pathology*
  • Receptors, Retinoic Acid / physiology*
  • Retroviridae / genetics
  • Telomerase / genetics*
  • Telomere

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • DNA-Binding Proteins
  • Receptors, Retinoic Acid
  • retinoic acid receptor beta
  • Telomerase